碳霉氨糖 | 519-21-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 碳霉氨糖
• 英文名称: 3-dimethylamino-3,6-dideoxy-β-D-glucopyranose
• 英文别名: 3-Dimethylamino-3,6-didesoxy-β-D-glucopyranose；3-Dimethylamino-3,6-didesoxy-D-glucose；Mycaminose；(2R,3S,4S,5R)-3-(dimethylamino)-2,4,5-trihydroxyhexanal
• CAS: 519-21-1
• 化学式: C₈H₁₇NO₄
• 分子量: 191.227
• InChiKey: IJUPCLYLISRDRA-ULAWRXDQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  81
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  碳霉氨糖 、 乙酸酐 在 吡啶 作用下， 生成 1,2,4-tri-O-acetyl-D-mycaminose
  参考文献：
  名称：

  Magnamycin B, a Second Antibiotic from Streptomyces halstedii

  摘要：

  DOI：

  10.1021/ja01649a020

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] AMPHETAMINE PRODRUGS<br/>[FR] PRO-MÉDICAMENTS À BASE D'AMPHÉTAMINES
  申请人：SHIRE AG

  公开号：WO2014002039A1

  公开（公告）日：2014-01-03

  The present invention relates to amphetamine prodrugs which provide colonic release of amphetamine.

  本发明涉及提供苯丙胺结肠释放的苯丙胺前药。
• [EN] POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS<br/>[FR] CONSTRUCTIONS POLYNUCLÉOTIDIQUES CONTENANT DES GROUPES DISULFURE
  申请人：SOLSTICE BIOLOG LTD

  公开号：WO2015069932A1

  公开（公告）日：2015-05-14

  The invention features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains one or more bulky groups proximal to the disulfide group. The invention also features polynucleotide constructs containing one or more components (i) containing a disulfide linkage, where each of the one or more components (i) is attached to an internudeotide bridging group or a terminal group of the polynucleotide construct, and each of the one or more components (i) contains at least 4 atoms in a chain between the disulfide linkage and the phosphorus atom of the internudeotide bridging group or the terminal group; and where the chain does not contain a phosphate, an amide, an ester, or an alkenylene. The invention also features methods of delivering a polynucleotide to a cell using the polynucleotide constructs of the invention.

  该发明涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）包含靠近二硫键的一个或多个臃肿基团。该发明还涉及包含一个或多个组分（i）的聚核苷酸构造，其中每个一个或多个组分（i）连接到聚核苷酸构造的一个核苷酸桥连基团或末端基团上，每个一个或多个组分（i）在二硫键和核苷酸桥连基团或末端基团的磷原子之间的链中至少包含4个原子；并且该链不包含磷酸酯、酰胺、酯或烯基烃。该发明还涉及使用该发明的聚核苷酸构造将聚核苷酸传递到细胞的方法。
• [EN] AMINE SALT OF CARBOSTYRIL DERIVATIVE<br/>[FR] SEL AMINE D'UN DERIVE DE CARBOSTYRILE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2005070892A1

  公开（公告）日：2005-08-04

  The invention provides an amine salt of a carbostyril derivative formed from a carbostyril derivative represented by the formula (1) [wherein R is a halogen atom; the substituted position of the side chain is 3- or 4-position in the carbostyril skeleton; and the bonding between 3- and 4-positions of the carbostyril skeleton is a single bond or a double bond] and an amine; and the invention is useful as drugs for treating various diseases, especially as aqueous formulations due to the superior water solubility and the superior pharmacologic effects.

  该发明提供了一种氨盐，该氨盐由一种由化学式（1）表示的卡波司替衍生物形成，其中R是卤素原子；侧链的取代位置在卡波司替骨架的3-或4-位置；卡波司替骨架的3-和4-位置之间的键合是单键或双键，并且与氨基；该发明可用作治疗各种疾病的药物，特别是由于其优越的水溶性和卓越的药理效果而作为水溶性制剂。
• ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES
  申请人：Arcturus Therapeutics, Inc.

  公开号：US20210060168A1

  公开（公告）日：2021-03-04

  ASGP-R binding molecular conjugates are provided. The conjugates are useful to deliver therapeutically effective amounts of biologically active molecules to target cells and tissues of a subject. Compositions are also provided comprising the molecular conjugates.

  提供ASGP-R结合分子共轭物。这些共轭物可用于将治疗有效量的生物活性分子传递给受试者的靶细胞和组织。还提供包含这些分子共轭物的组合物。